UnknownNot Applicable

Effects of Medisinstart for Type 2 Diabetes

Norway500 participantsStarted 2024-02-07

Plain-language summary

Medisinstart is a counseling service in pharmacies where patients who start taking a new medicine receive two follow-up appointments with a pharmacist. The aim of the service is to promote correct medication use and increase patient adherence. The effect of Medisinstart has previously been studied among patients starting a new cardiovascular drug. The aim of the project is to map the effects of Medisinstart among patients starting a new medication for type 2 diabetes. Knowledge about the effects of Medisinstart is important in order to maximize the benefits of the service for patients and society. The project is being conducted as a randomized controlled trial among adult patients starting a new medication for type 2 diabetes. The intervention group receives Medisinstart, while the control group only receives prescription dispensing as normal. Data collection includes HbA1c analysis in blood samples and responses to questionnaires. HbA1c is an established measure of glycemic control.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Extracted a new drug/active substance (A10A/A10B) for type 2 diabetes * Age ≥ 18 years * The drugs are administered by the patient/relatives * Good command of Norwegian, both written and spoken Exclusion Criteria: * Inability to understand and/or complete consent forms, questionnaires and/or other patient-oriented materials * Not able to attend physical appointments in the pharmacy * Not given written consent to participate in the study * Diabetes medication is administered by a healthcare professional * Known pregnancy * HbA1c is unsuitable as an average measure of blood glucose at baseline * Received initiation of medication for type 2 diabetes within the last year * Ongoing participation in other studies involving similar interventions to increase adherence and ensure correct medication use

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

HbA1c

Timeframe: At baseline and 6 months after initation of the new medication for type 2 diabetes.

HbA1c

Timeframe: At baseline and 12 months after initation of the new medication for type 2 diabetes.

Trial details

NCT IDNCT06273657

SponsorApokus AS

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02

Contact for this trial

Sara Bremer, PhD

21620200 sara@apokus.no

View on ClinicalTrials.gov More Type 2 Diabetes trials